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Statins are widely used to prolong survival and reduce the occurrence of coronary and cerebrovascular events in 
patients with and without cardiovascular disease. Prior meta-
analyses have demonstrated the effectiveness of statins for 
the primary and secondary prevention of cardiovascular dis-
ease,1–5 with consistent benefits across subgroups, including 
the elderly,6 women,7 and individuals with diabetes mellitus.2 
Initially focused on secondary prevention, statin therapy has 
become more common because the limits of treatment have 
expanded over time to include people at progressively lower 
risk of developing cardiovascular disease.8 As the number of 
individuals eligible for statin therapy continues to increase,9 
the comparative tolerability and harms of different statins war-
rant further investigation.
There is no comprehensive analysis on the comparative 
adverse event profiles of different statins, which builds on the 
totality of the existing randomized, controlled trial evidence 
base. Although large-scale meta-analyses confirmed that the 
frequency of clinically significant side effects associated with 
statin therapy is low,10 more research is needed to synthesize the 
evidence on a more diverse range of outcomes that are important 
for individuals receiving statins. These range from previously 
studied outcomes, such as cancer11–13 and diabetes mellitus,14,15 
to muscle aches and clinically meaningful elevations in liver 
enzymes, which may be among factors contributing to nonad-
herence to long-term statin therapy.16,17 Information regarding 
the relative tolerability and harms of different statins in the 
prevention of cardiovascular disease is needed to better inform 
patients, clinicians, and other healthcare decision makers.
Several reviews established the favorable safety profile of 
statins.18–22 An important limitation of previous reviews is 
their focus on placebo-controlled trials, which did not take 
into account evidence from a large number of trials with direct 
head-to-head comparisons of statins. Equally important, 
Background—Our objective was to estimate the comparative harms of individual statins using both placebo-controlled and 
active-comparator trials.
Methods and Results—We systematically reviewed randomized trials evaluating different statins in participants with and 
without cardiovascular disease. We performed random-effects pairwise and network meta-analyses to quantify the relative 
harms of individual statins. We included 55 two-armed placebo-controlled and 80 two- or multiarmed active-comparator 
trials including 246 955 individuals. According to pairwise meta-analyses, individual statins were not different than 
control in terms of myalgia, creatine kinase elevation, cancer, and discontinuations because of adverse events. Statins 
as a class resulted in significantly higher odds of diabetes mellitus (odds ratio, 1.09; 95% confidence interval, 1.02–
1.16) and transaminase elevations (odds ratio, 1.51; 95% confidence interval, 1.24–1.84) compared with control. When 
individual statins were compared in network meta-analyses, there were numerous statistically detectable differences, 
favoring simvastatin and pravastatin. According to dose-level comparisons, individual statins resulted in higher odds of 
discontinuations with higher doses of atorvastatin and rosuvastatin. Similarly, higher doses of atorvasatin, fluvastatin, 
lovastatin, and simvastatin were associated with higher odds of transaminase elevations. Simvastatin at its highest doses 
was associated with creatine kinase elevations (odds ratio, 4.14; 95% credible interval, 1.08–16.24). Meta-regression 
analyses adjusting for study-level age at baseline, low-density lipoprotein cholesterol level, and publication year did not 
explain heterogeneity. There was no detectable inconsistency in the network.
Conclusions—As a class, adverse events associated with statin therapy are not common. Statins are not associated with 
cancer risk but do result in a higher odds of diabetes mellitus. Among individual statins, simvastatin and pravastatin seem 
safer and more tolerable than other statins.  (Circ Cardiovasc Qual Outcomes. 2013;06:390-399.)
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previous reviews did not assess differences in dosages of indi-
vidual statins across populations and did not compare statins 
at similar doses.
Our objective in this study was to systematically review 
and synthesize the totality of the randomized, controlled trial 
evidence on different statins and determine their comparative 
tolerability and harms across a range of populations eligible 
for statin therapy.
Methods
Systematic Review
Our search strategy was based on a publicly available protocol pre-
viously developed by the study authors to evaluate the comparative 
clinical benefits of statins.23 We searched MEDLINE, EMBASE, 
Cochrane Database of Systematic Reviews, and Cochrane Central 
Register of Controlled Trials to identify studies published between 
January 1, 1985, and March 10, 2013. To identify the relevant lit-
erature, we developed a search strategy using the search terms ator-
vastatin, fluvastatin, simvastatin, lovastatin, pravastatin, rosuvastatin, 
cholesterol, cardiovascular disease, and hydroxymethylglutaryl-co-
enzyme A reductase inhibitors/therapeutic use. Our updated search 
in MEDLINE adopted Cochrane Collaboration’s sensitivity and pre-
cision-maximizing strategy.24 We searched for pitavastatin trials post 
hoc separately because our protocol did not include pitavastatin (pro-
tocol finalization coincided with the Food and Drug Administration 
approval of this agent). We also performed manual searches using 
the authors’ files and reference lists from original communications 
and review articles to cross-check references. Two researchers (B.T., 
H.T.) independently performed abstract, title, and full-text screening. 
A third researcher approved study selection (H.N.).
We included open-label and double-blind randomized, controlled 
trials comparing one statin with another at any dose or with control 
(placebo, diet, or usual care) for adults with, or at risk of developing, 
cardiovascular disease. We included trials of atorvastatin, fluvastatin, 
lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin if 
they had >50 participants per trial arm and lasted >4 weeks based on 
prespecified inclusion and exclusion criteria.
Outcomes of interest were determined after protocol finalization. 
We included trials that reported tolerability (number of participants 
who discontinued the study medication because of adverse events), 
elevations in hepatic transaminases (number of participants with 
clinically meaningful elevations in either alanine aminotransferase or 
aspartate aminotransferase, 3× baseline values as commonly defined 
by trial investigators), elevations in creatine kinase (CK; number of 
participants with clinically meaningful increases in baseline CK lev-
els as defined by trial investigators, ranging from 3× to 10× higher 
than baseline concentrations), myalgia (number of individuals with 
muscle pain, as defined by trial investigators), myopathy (number 
of participants with 10× baseline CK levels associated with muscle 
symptoms), and rhabdomyolysis (number of participants with severe 
muscle damage, as diagnosed by trial investigators). In addition, we 
were interested in the incidence of cancer and diabetes mellitus (as 
defined by trial investigators), so trials reporting these outcomes were 
also eligible for inclusion. Both fixed dose and titration designs were 
included. As per our protocol, we excluded trials conducted in pa-
tients with renal insufficiency.
We used a structured form developed in MS Excel to extract data 
on trial and patient population characteristics and outcomes. We also 
extracted information on the methodological quality of included stud-
ies. In particular, information was collected on blinding, random se-
quence generation, allocation concealment, indications of incomplete 
outcome data, indications of selective reporting (possible for trials 
with published protocols), and industry sponsorship. One researcher 
extracted data (H.N.) and another independently checked for accu-
racy (B.T.).
Statistical Analysis
We qualitatively summarized included trials, describing the types of 
direct and indirect comparisons and important clinical and trial design 
characteristics. For each pairwise comparison between 2 treatments, 
we calculated the relative effect with a 95% confidence interval (CI). 
We performed classical pairwise meta-analyses to synthesize studies 
that compared the same 2 treatments using the DerSimonian–Laird 
(random-effects) method. Forest plots of the relative treatment effects 
from the individual trials and pairwise meta-analyses were visually 
inspected to search for heterogeneity. We also statistically inspected 
heterogeneity using the I2 measure.
To determine the comparative tolerability and harms of individual 
statins, we conducted network meta-analyses, which are generaliza-
tions of indirect comparisons with >2 (or multiple pairs of) treatments 
being compared indirectly and ≥1 pair of treatments compared both 
directly and indirectly.25,26 This type of analysis allowed for simul-
taneously combining the direct within-trial comparisons between 2 
treatments (eg, atorvastatin versus control) with indirect comparisons 
constructed from trials that had 1 treatment in common (eg, atorvas-
tatin versus control and simvastatin versus control).27 This analysis 
preserved the within-trial randomized treatment comparison of each 
trial while combining all available comparisons between treatments. 
We combined study-level relative treatment effects using Bayesian 
Markov chain Monte Carlo methods in WinBUGS version 1.4.3. We 
used the model developed by Dias et al28 for the UK National Institute 
of Health Clinical Excellence Decision Support Unit. This was based 
on modeling the outcomes in every treatment group of every study 
and specifying the relationships among the relative effects across 
studies making different comparisons, while taking into account the 
correlations between treatment effects within multiarm trials. Our 
models adopted random effects. The random-effects model took into 
account potential heterogeneity by assuming that each treatment was 
drawn from the same distribution, whose mean and variance were 
estimated from the data.29 Additional details of our analytic approach 
are provided in the online-only Data Supplement Appendix.
Findings were reported in terms of odds ratios (OR). The differ-
ence between treatments was assessed on the basis of 95% CI in 
pairwise meta-analyses and 95% credible intervals (CrI) in network 
meta-analyses. CrIs may be interpreted as Bayesian equivalents of 
95% CIs. The 95% CrI can be interpreted as indicating a 95% prob-
ability that the true OR falls within the reported range. If a 95% CrI 
does not include the null value 1.00, this can be interpreted as in-
dicating <5% probability that there is no difference between the 2 
comparators (referred to as significant difference between treatments 
hereafter). Given the Bayesian nature of the statistical analyses, P 
values are not estimated and reported for network meta-analyses.
WHAT IS KNOWN
•	 The frequency of clinically significant side effects 
associated with statin therapy is low.
•	 There is no comprehensive analysis on the compara-
tive adverse event profiles of different statins that 
builds on both placebo-controlled and active-com-
parator trials.
WHAT THE STUDY ADDS
•	 Higher doses of some statins are associated with 
larger numbers of transaminase and creatine kinase 
elevations, and discontinuations because of adverse 
events.
•	 There are clinically meaningful differences among 
individual statins, with simvastatin and pravastatin 
likely to be ranked superior to their alternatives in 
terms of their safety profile.
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We assessed the probability that each statin has the most favorable 
harm profile by calculating its treatment effect compared with control 
treatment and counting the proportion of iterations for which each 
statin has the highest treatment effect (ie, least harmful), the second 
highest, and so on. This approach took into account the magnitude of 
the estimated treatment effect, as well as the uncertainty around it. We 
graphically presented the distribution of ranking probabilities and es-
timated the surface under the cumulative ranking line for each statin.30 
The surface under the cumulative ranking line for each statin would 
be 1.00 when a treatment is certain to be the best (most favorable 
tolerability and harm profile) and 0.00 when a treatment is certain to 
be the worst (least favorable tolerability and harm profile). Ranking 
probabilities were estimated for the 4 outcomes with the most data 
(discontinuations because of adverse events, myalgia, elevations in 
hepatic transaminases, and elevations in CK levels) and combined in 
a composite measure with each of the 4 outcomes contributing 0.25 
to the total ranking score of 1.00.
To obtain a comprehensive estimate of the comparative tolerability 
and harms of individual statins, our network meta-analysis pooled 
all primary and secondary prevention trials in addition to trials with 
mixed patient populations, including all placebo-controlled and 
active-comparator trials eligible for inclusion in this review. In sub-
group analyses, we also investigated the comparative effects of indi-
vidual statins in primary and secondary prevention separately.
Primary analyses were at the drug level (referred to as drug-level net-
work meta-analyses hereafter), comparing individual statins to each oth-
er (eg, atorvastatin versus simvastatin). Sensitivity analyses were dose 
specific and explored the comparative harms of individual statins at dif-
ferent doses separately (referred to as dose level hereafter). Each statin–
dose combination was treated as a different treatment, and no trends 
were fitted or assumed. The following daily doses were considered for 
atorvastatin, lovastatin, pravastatin, and simvastatin: ≤10 mg, >10 and 
≤20 mg, >20 and ≤40 mg, and >40 mg. For fluvastatin, daily doses 
were ≤20 mg, >20 and ≤40 mg, and >40 mg. For rosuvastatin, the daily 
doses were ≤5 mg, >5 and ≤10 mg, >10 and ≤20 mg, and >20 mg. For 
pitavastatin, 2 and 4 mg/d formulations were considered. All analyses 
were based on the total number of randomly assigned participants.
We investigated whether potential heterogeneity and inconsistency 
across the evidence base in the network meta-analysis of discontinu-
ations, myalgia, transaminase elevations, and CK elevations could 
be explained by mean age at baseline, mean low-density lipoprotein 
cholesterol concentration at baseline, or the publication year of the 
trial using meta-regression analyses. All meta-regression analyses al-
lowed for a common treatment–covariate interaction for each statin 
compared with control.31 An additional sensitivity analysis excluded 
open-label trials and explored the comparative harms and tolerability 
of individual statins in double-blind trials.
For all outcomes, we also qualitatively evaluated the consistency of 
relative treatment effects obtained from an analysis of head-to-head 
trials with those obtained from an analysis combining both placebo-
controlled and active-comparator trials. In particular, we first per-
formed pairwise meta-analyses on all available direct comparisons 
(ie, direct evidence) and then compared the findings of these pairwise 
meta-analyses with the results of network meta-analysis (ie, mixed 
evidence). The consistency of the relative treatment effects was visu-
ally inspected for potential differences between estimates obtained 
from 2 sets of analyses (ie, direct and mixed estimates). We checked 
for discrepancy in terms of the direction of effect, as well as its 
magnitude, and confirmed that all 95% intervals greatly overlapped, 
which suggested adequate consistency. We also evaluated small-study 
effects using contour-enhanced funnel plots, which tested a compos-
ite hypothesis of publication and reporting bias, and chance.
Figure 1. Flow diagram 
of trial identification and 
selection.
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Results
Our review included 135 trials (Figure 1), totaling 246 955 
participants. Overall, the average trial follow-up was 68 weeks 
(1.3 years). There were 55 two-armed placebo-controlled 
trials, and the remaining 80 were 2-armed or multiarmed 
active-comparator trials. Of the 28 possible pairwise com-
parisons between the 8 treatments (7 statins and control), 22 
were available. Most frequent comparisons occurred between 
pravastatin and placebo, atorvastatin and placebo, and rosuv-
astatin and atorvastatin. A total of 53 325 participants received 
atorvastatin, whereas 35 404 participants received simvastatin 
and 29 557 received pravastatin. No trial directly compared 
all 7 statins with each other for the drug-level comparison 
(Figure 2). Similarly, a small number of fluvastatin, lovastatin, 
and pitavastatin trials contributed to the dose-level network 
meta-analysis. No trial directly compared all statin–dose com-
binations with each other (Figure 3). Based on analyses on 
discontinuations because of adverse events, myalgia, trans-
aminase elevations, and CK elevations, there was no evidence 
of differential effects between more precise and less precise 
trials according to contour-enhanced funnel plots (ie, no evi-
dence of small-study effects).
The overall methodological quality of included trials was 
moderate. Older trials had lower methodological quality with 
inadequate sequence generation and treatment allocation con-
cealment. A large number of trials did not report details about 
randomization procedures and allocation concealment. Only 
11 trials had high methodological quality on all 6 items.
Discontinuations Because of Adverse Events
According to the pairwise meta-analysis of placebo-con-
trolled trials including 76 462 participants, statins as a class 
were not significantly different than control (OR, 0.95; 95% 
CI, 0.83–1.08; I2, 21.9%). In the trials that directly com-
pared individual statins head-to-head, simvastatin was sig-
nificantly more tolerable than atorvastatin (OR, 0.61; 95% 
CI, 0.42–0.89; I2, 71.9%) and rosuvastatin (OR, 0.49; 95% 
CI, 0.27–0.88; I2, 0.0%).
In the drug-level network meta-analysis of individual statins, 
131 503 participants contributed information on 7811 events 
(6% of all participants). Individual statins were similar to con-
trol in terms of discontinuations because of adverse events 
(Figure 4A). When compared head-to-head, participants ran-
domized to pravastatin (OR, 1.46; 95% CrI, 1.10–1.92) and 
simvastatin (OR, 1.34; 95% CrI, 1.06–1.69) were significantly 
less likely to stop treatment because of adverse events com-
pared with those randomized to atorvastatin (Table 1).
The dose-level network meta-analysis of discontinua-
tions because of adverse events included 151 823 partici-
pants, providing information on 8719 discontinuations. 
Atorvastatin at >20 and ≤40 mg/d (OR, 2.72; 95% CrI, 
1.46–5,09) and atorvastatin at >40 mg/d (OR, 1.69; 95% 
CrI, 1.18–2.44) led to significantly more discontinuations 
compared with control. There was no strong dose–response 
relationship for most statin–dose combinations (higher 
doses did not necessarily result in higher discontinuation 
rates; Figure 5A).
Myalgia
When the placebo-controlled trials of statins were pooled 
as a class in a pairwise meta-analysis including 43 531 par-
ticipants, statins were not significantly different than con-
trol treatment (OR, 1.07; 95% CI, 0.89–1.29; I2, 22.1%) in 
terms of myalgia incidence. The pairwise meta-analysis of 
head-to-head simvastatin versus atorvastatin trials showed 
that participants randomized to simvastatin had lower odds of 
experiencing myalgia compared with those receiving atorvas-
tatin (OR, 0.56; 95% CI, 0.42–0.75; I2, 0.0%).
Although the direction and magnitude of the difference 
between simvastatin and atorvastatin were similar in the drug-
level network meta-analysis, there was greater variability 
around this estimate when all eligible direct and indirect trials 
were combined (OR, 0.78; 95% CrI, 0.55–1.13; reciprocals 
Control
Atorvastatin
Fluvastatin
Lovastatin
Pravastatin
Rosuvastatin
Simvastatin
Pitavastatin
Figure 2. Network of available comparisons for the drug-level 
analysis. Connecting lines indicate the existing direct pairwise 
comparisons between 2 treatments. The width of the lines is 
proportional to the number of pairwise comparisons between 
2 treatments, and the size of every node is proportional to the 
number of participants.
Control Atorva ≤10
Atorva >10 and ≤20
Atorva >20 and ≤40
Atorva >40
Fluva ≤20
Fluva >20 and ≤40
Fluva >40
Lova ≤10
Lova >10 and ≤20
Lova >20 and ≤40
Lova >40
Prava ≤10
Prava >10 and ≤20
Prava >20 and ≤40
Prava >40
Rosuva ≤5
Rosuva >5 and ≤10
Rosuva >10 and ≤20
Rosuva >20
Simva ≤10
Simva >10 and ≤20
Simva >10 and ≤20
Simva >40
Pita 2
Pita 4
Figure 3. Network of available comparisons for dose-specific 
analysis. Connecting lines indicate the existing direct pairwise 
comparisons between 2 treatments. The width of the lines is 
proportional to the number of pairwise comparisons between 
2 treatments, and the size of every node is proportional to the 
number of participants.
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reported in Table 1). According to the findings of the network 
meta-analysis including 84 391 participants with 1986 myal-
gia events (2% of all participants), there were no significant 
differences between individual statins.
In the dose-level network meta-analysis including 99 433 
participants with 2533 events, there was a lack of an apparent 
dose–response relationship for myalgia (Figure 5B) with no 
statistically detectable differences between individual statin–
dose combinations and control treatment.
Transaminase Elevations
The pairwise meta-analysis of placebo-controlled trials 
including 122 665 participants showed that participants ran-
domized to statins had significantly higher odds of experienc-
ing alanine aminotransferase and aspartate aminotransferase 
elevations compared with those randomized to control (OR, 
1.51; 95% CI, 1.24–1.84; I2, 52.3%). Among the trials that 
directly compared pravastatin and atorvastatin, participants 
randomized to pravastatin had significantly lower odds of 
transaminase elevations (OR, 0.27; 95% CI, 0.10–0.74; I2, 
61.3%).
In the drug-level network meta-analysis of individual 
statins, 165 534 participants contributed information on 2075 
clinically meaningful elevations in hepatic transaminases (1% 
of all participants). Individuals randomized to atorvastatin 
(OR, 2.55; 95% CrI, 1.71–3.74) and fluvastatin (OR, 5.18; 
95% CrI, 1.89–15.55) had higher odds of transaminase eleva-
tions (Figure 4C). When compared head-to-head, pravastatin 
(OR, 0.39; 95% CrI, 0.24–0.65), rosuvastatin (OR, 0.63; 95% 
CrI, 0.42–0.94), and simvastatin (OR, 0.45; 95% CrI, 0.28–
0.73) had lower odds of transaminase elevations compared 
1.10 (0.86, 1.49)
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0.81 (0.63, 1.05)
1.14 (0.89, 1.48)
0.89 (0.68, 1.17)
0.92 (0.44, 1.96)
0.01 0.10 1.00 10.00 100.00
Atorva
Fluva
Lova
Prava
Rosuva
Simva
Pitava
OR (log scale)
2.55 (1.71, 3.74)
5.18 (1.89, 15.55)
2.03 (0.99, 4.16)
1.00 (0.65, 1.54)
1.59 (1.02, 2.50)
1.16 (0.71, 1.88)
2.85 (0.77, 11.16)
0.10 1.00 10.00 100.00
OR (log scale)
1.39 (0.86, 2.17) 
0.25 (0.06, 1.06)
1.05 (0.55, 2.20)
1.24 (0.85, 1.88)
1.39 (0.85, 2.30)
1.23 (0.68, 2.15)
3.63 (1.10, 14.10)
0.01 0.10 1.00 10.00 100.00
Atorva
Fluva
Lova
Prava
Rosuva
Simva
Pitava
OR (log scale)
0.83 (0.65, 1.07)
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0.98 (0.81, 1.20)
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Figure 4. Findings of drug-level network meta-analyses: effect of statins compared with control on (A) discontinuations because of 
adverse events, (B) occurrence of myalgia, (C) clinically meaningful elevation in hepatic transaminases, (D) clinically meaningful elevation 
in CK levels, (E) incidence of cancer, and (F) incidence of diabetes mellitus. There were no data to estimate cancer incidence with 
pitavastatin and diabetes mellitus incidence with fluvastatin and pitavastatin. CK indicates creatine kinase; OR, odds ratio.
Table 1. Findings of Drug-Level Network Meta-Analyses, Showing the OR Comparing Statins (95% Credible Interval): Comparative 
Head-to-Head Effects of Individual Statins on Myalgia (top half of the table) and Discontinuations Because of Adverse Events 
(bottom half of the table)
Atorvastatin 1.08 (0.56, 2.17) 0.87 (0.54, 1.46) 1.1 (0.77, 1.53) 0.88 (0.71, 1.08) 1.28 (0.88, 1.80) 0.49 (0.15, 1.42)
0.97 (0.64, 1.47) Fluvastatin 0.81 (0.37, 1.71) 1.02 (0.48, 2.02) 0.82 (0.40, 1.58) 1.19 (0.56, 2.37) 0.46 (0.12, 1.52)
1.30 (0.87, 1.94) 1.33 (0.83, 2.14) Lovastatin 1.26 (0.7, 2.15) 1.00 (0.58, 1.68) 1.46 (0.80, 2.54) 0.57 (0.15, 1.79)
1.46 (1.10, 1.92) 1.50 (0.97, 2.33) 1.13 (0.75, 1.7) Pravastatin 0.80 (0.55, 1.19) 1.17 (0.74, 1.82) 0.45 (0.13, 1.35)
1.04 (0.85, 1.27) 1.07 (0.69, 1.65) 0.80 (0.52, 1.22) 0.71 (0.52, 0.97) Rosuvastatin 1.46 (0.98, 2.14) 0.56 (0.17, 1.64)
1.34 (1.06, 1.69) 1.37 (0.89, 2.14) 1.03 (0.67, 1.57) 0.91 (0.67, 1.26) 1.28 (0.98, 1.69) Simvastatin 0.39 (0.12, 1.12)
1.29 (0.62, 2.66) 1.32 (0.57, 3.06) 0.99 (0.43, 2.26) 0.88 (0.41, 1.89) 1.24 (0.59, 2.58) 0.96 (0.46, 2.02) Pitavastatin
Comparisons between drugs should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining 
treatment. For both outcomes, ORs <1 favor the column-defining treatment. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. OR 
indicates odds ratio.
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with atorvastatin (reciprocals reported in Table 2). Fluvastatin 
resulted in significantly higher odds of elevations than pravas-
tatin (OR, 5.19; 95% CrI, 1.75–16.73), rosuvastatin (OR, 3.25; 
95% CrI, 1.08–10.50), and simvastatin (OR, 4.50; 95% CrI, 
1.49–14.19).
The dose-level network meta-analysis for clinically mean-
ingful elevations in hepatic transaminases included 188 503 
participants, providing information on 2298 events. There was 
a clear dose–response relationship for atorvastatin, lovastatin, 
and simvastatin, with higher doses resulting in higher odds 
of transaminase elevations (Figure 5C). Individuals receiv-
ing simvastatin at ≤10 mg/d had lower odds of experienc-
ing transaminase elevations compared with those receiving 
control (OR, 0.41; 95% CrI, 0.18–0.85). Atorvastatin at >20 
and ≤40 mg/d (OR, 2.42; 95% CrI, 1.10–5.55), atorvastatin at 
>40 mg/d (OR, 5.25; 95% CrI, 3.89–7.24), fluvastatin at >40 
mg/d (OR, 4.16; 95% CrI, 1.60–14.36), and simvastatin at >40 
mg/d (OR, 2.83; 95% CrI, 1.47–5.87) resulted in significantly 
higher odds of elevations than control.
CK Elevations
When the placebo-controlled trials of statins were pooled in a 
pairwise meta-analysis including 101 324 participants, statins 
as a class were not significantly different than control treatment 
(OR, 1.13; 95% CI, 0.85–1.51; I2, 20.4%). In the drug-level 
network meta-analysis of individual statins, 127 571 partici-
pants provided information on 721 individuals with clinically 
meaningful CK elevations (0.6% of all participants). Accord-
ing to this analysis, pitavastatin resulted in significantly more 
CK elevations than control treatment (OR, 3.63; 95% CrI, 
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Figure 5. Findings of dose-level network meta-analyses: effects of statin–dose combinations compared with control on (A) 
discontinuations because of adverse events, (B) occurrence of myalgia, (C) clinically meaningful elevation in hepatic transaminases, and 
(D) clinically meaningful elevation in CK levels. CK indicates creatine kinase; OR, odds ratio.
Table 2. Findings of Drug-Level Network Meta-Analyses: Comparative Head- to-Head Effects of Individual Statins on CK (top half 
of the table) and Transaminase Elevations (bottom half of the table).
Atorvastatin 5.59 (1.22, 25.52) 1.32 (0.54, 2.88) 1.13 (0.65, 1.78) 0.99 (0.64, 1.53) 1.13 (0.65, 1.97) 0.38 (0.10, 1.23)
0.49 (0.15, 1.42) Fluvastatin 0.24 (0.05, 1.17) 0.20 (0.04, 0.88) 0.18 (0.04, 0.81) 0.20 (0.04, 0.94) 0.07 (0.01, 0.46)
1.26 (0.57, 2.73) 2.58 (0.76, 9.03) Lovastatin 0.84 (0.39, 1.94) 0.76 (0.34, 1.85) 0.86 (0.37, 2.23) 0.29 (0.06, 1.18)
2.55 (1.54, 4.14) 5.19 (1.75, 16.73) 2.03 (0.90, 4.56) Pravastatin 0.89 (0.51, 1.63) 1.01 (0.55, 2.00) 0.34 (0.09, 1.18)
1.60 (1.06, 2.38) 3.25 (1.08, 10.5) 1.27 (0.55, 2.93) 0.63 (0.36, 1.10) Rosuvastatin 1.14 (0.62, 2.19) 0.38 (0.10, 1.23)
2.20 (1.36, 3.52) 4.50 (1.49, 14.19) 1.76 (0.75, 4.12) 0.87 (0.47, 1.57) 1.38 (0.79, 2.38) Simvastatin 0.34 (0.08, 1.13)
0.89 (0.24, 3.23) 1.82 (0.34, 10.00) 0.71 (0.16, 3.13) 0.34 (0.08, 1.35) 0.55 (0.15, 2.04) 0.40 (0.10, 1.56) Pitavastatin
CK, creatine kinase. Comparisons between drugs should be read from left to right, and the estimate is in the cell in common between the column-defining treatment 
and the row-defining treatment. For both outcomes, ORs <1 favor the column-defining treatment. To obtain ORs for comparisons in the opposite direction, reciprocals 
should be taken. OR indicates odds ratio.
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1.10–14.10; Figure 4D). Individuals randomized to fluvastatin 
had significantly lower odds of experiencing CK elevations 
compared with all other statins, except for lovastatin (Table 2).
The dose-level network meta-analysis for clinically mean-
ingful elevations in baseline CK levels included 137 980 
participants, providing information on 778 individuals who 
experienced elevations. There was a small dose–response 
relationship with lovatatin and simvastatin, with higher doses 
resulting in higher odds of elevations (Figure 4D). Simvastatin 
at >40 mg/d resulted in significantly higher odds of experi-
encing elevations compared with control treatment (OR, 4.14; 
95% CrI, 1.08–16.24).
Cancer
The pairwise meta-analysis of placebo-controlled trials includ-
ing 100 523 participants showed that statins as a class were not 
significantly different than control treatment (OR, 0.96; 95% 
CrI, 0.91–1.02; I2, 0.0%). Similarly, there was no evidence 
from the drug-level network meta-analyses that individual 
statins were different than control treatment on the basis of 
5511 cancer occurrences among 105 450 participants (5.2% 
of all participants). There was also no evidence of potential 
head-to-head differences between individual statins (Table 3).
Diabetes Mellitus
On the basis of placebo-controlled trials including 113 698 
participants, the pairwise meta-analysis showed that statins 
as a class were statistically significantly different than con-
trol (OR, 1.09; 95% CrI, 1.02–1.16; I2, 2.8%). According to 
placebo-controlled trials, rosuvastatin resulted in significantly 
higher odds of diabetes mellitus compared with control (OR, 
1.16; 95% CI, 1.02–1.31; I2, 0.0%). However, the drug-level 
network meta-analysis did not achieve statistical significance 
for any of the individual statins as a result of wider 95% CrIs 
(rosuvastatin had a similar effect size estimate in both pairwise 
and network meta-analyses; Figure 4D). Also, there were no 
statistically detectable differences between individual statins 
in terms of diabetes mellitus incidence (Table 3).
Additional Outcomes
There was limited information on both myopathy and rhabdo-
myolysis outcomes. In the drug-level network meta-analysis, 
individual statins were not significantly different than control: 
atorvastatin (OR, 1.21; 95% CrI, 0.25–4.95), pravastatin (OR, 
1.06; 95% CrI, 0.18–4.81), rosuvastatin (OR, 0.91; 95% CrI, 
0.12–4.43), and simvastatin (OR, 1.23; 95% CrI, 0.29–4.21). 
There was no evidence of potential differences between indi-
vidual statins in terms of myopathy outcomes (results not 
shown). Similarly, drug-level network meta-analysis showed 
that individual statins were not different than control treat-
ment in terms of rhabdomyolysis: atorvastatin (OR, 1.33; 95% 
CrI, 0.31–6.92), pravastatin (OR, 0.20; 95% CrI, 0.00–11.15), 
rosuvastatin (OR, 0.19; 95% CrI, 0.00–9.22), and simvastatin 
(OR, 2.03; 95% CrI, 0.40–14.81). There were no statistically 
detectable differences between individual statins in terms of 
rhabdomyolysis.
When the individual statins were ranked in terms of the mag-
nitude of the estimated treatment effect, as well as the uncer-
tainty around it, pravastatin (0.71) and simvastatin (0.70) had 
the highest combined score out of a total of 1.00, suggesting that 
these statins had the most favorable tolerability and harm pro-
file on the basis of discontinuations because of adverse events, 
myalgia, transaminase elevations, and CK elevations (Figure 6). 
Baseline low-density lipoprotein cholesterol concentration, 
baseline mean age of the study population, and publication year 
did not explain the observed heterogeneity in the evidence base. 
Estimate of between-study heterogeneity in the drug-level net-
work meta-analyses did not decrease in meta-regression anal-
yses. According to the sensitivity analyses, findings from the 
base-case network meta-analyses did not change when adjusting 
for baseline low-density lipoprotein cholesterol concentration, 
mean age, and publication year in meta-regression analyses, 
with statistically nonsignificant coefficients (results provided 
in the online-only Data Supplement Appendix). Limiting the 
analysis to double-blind trials also did not change the observed 
ORs. Although small sample size was a limitation of subgroup 
analyses, we did not obtain materially different comparative 
harm and tolerability estimates for individual statins in primary 
versus secondary prevention populations (results provided in 
the online-only Data Supplement Appendix).
Discussion
This network meta-analysis of 246 955 participants provides 
evidence on the comparative tolerability and harms of indi-
vidual statins using both placebo-controlled and active-com-
parator trials. Overall, statins as a class are associated with an 
increased risk of diabetes mellitus and hepatic transaminase 
elevations, with no statistically detectable effect on myalgia, 
myopathy, rhabdomyolysis, and cancer. Across the totality of 
the evidence base, higher doses of some statins result in higher 
Table 3. Findings of Drug-Level Network Meta-Analyses: Comparative Head- to-Head Effects of Individual Statins on Diabetes (top 
half of the table) and Cancer (bottom half of the table)
Atorvastatin - 1.18 (0.71, 1.99) 1.12 (0.79, 1.62) 1.01 (0.69, 1.47) 1.06 (0.72, 1.57)
0.94 (0.59, 1.47) Fluvastatin - - - -
0.86 (0.60, 1.20) 0.91 (0.58, 1.43) Lovastatin 0.95 (0.62, 1.46) 0.85 (0.54, 1.33) 0.90 (0.56, 1.41)
0.90 (0.69, 1.20) 0.97 (0.65, 1.45) 1.06 (0.81, 1.42) Pravastatin 0.90 (0.70, 1.12) 0.94 (0.72, 1.21)
0.84 (0.62, 1.16) 0.90 (0.58, 1.39) 0.99 (0.73, 1.36) 0.94 (0.73, 1.19) Rosuvastatin 1.05 (0.80, 1.40)
0.84 (0.66, 1.08) 0.90 (0.60, 1.37) 0.98 (0.75, 1.34) 0.93 (0.77, 1.15) 0.99 (0.78, 1.30) Simvastatin
Comparisons between drugs should be read from left to right, and the estimate is in the cell in common between the column-defining treatment and the row-defining 
treatment. For both outcomes, ORs <1 favor the column-defining treatment. To obtain ORs for comparisons in the opposite direction, reciprocals should be taken. OR 
indicates odds ratio.
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odds of experiencing transaminase elevations, CK eleva-
tions, and discontinuations because of adverse events. When 
compared head-to-head in network meta-analyses, there are 
differences among individual statins, with simvastatin and 
pravastatin likely to be ranked superior to their alternatives in 
terms of their safety profile.
Although the benefits of statins for individuals with estab-
lished cardiovascular disease are well documented,9 their 
effect in individuals free of cardiovascular disease has been 
disputed.8,32–34 Recent meta-analyses based on both individual 
patient-level data4 and study-level reports5 confirm that all-
cause mortality benefits of statins in the primary prevention 
setting are clinically and statistically significant. These recent 
findings provide supporting evidence for initiating statin ther-
apy in individuals who are at an increased risk of developing 
cardiovascular disease. Nevertheless, expanding the limits of 
statin therapy to a wider population of individuals may have 
important safety implications. Although rare, adverse events 
associated with statin therapy range from mild to moderate 
and seem to increase with treatment intensity. With notable 
exceptions,35 randomized trial evidence on the long-term 
safety of individual statin treatments remains limited.
Our review confirms the findings of previous pairwise 
meta-analyses in that statins as a class are associated with 
higher odds of developing diabetes mellitus15 and experi-
encing hepatic transaminase elevations.36 There is a lack of 
evidence that statins are associated with an increased risk of 
developing cancers. Although our review did not find statisti-
cal evidence of myopathy, this may be because of an underde-
tection of muscle toxicity in clinical trials.37–39
At the population level, mortality and cardiovascular ben-
efits of statin therapy greatly overweigh its potential harms, 
even taking into account the recent finding that statin use is 
associated with a modest increase in diabetes mellitus inci-
dence.40 At the individual level, however, there may be a 
risk of exposing a large group of individuals to the (primar-
ily minor) harms of statin therapy for the benefit of a smaller 
number of individuals. This brings into sharp focus the impor-
tance of correctly identifying the set of individuals who stand 
to benefit from statin therapy. There are emerging tools that 
can be used to predict personalized long-term harms and ben-
efits associated with statin therapy.41
Available statins differ to a various extent in pharmacologi-
cal properties, and it would be expected that they differ in 
terms of their clinical efficacy.42,43 Nonetheless, their compara-
tive harms had not been evaluated in a comprehensive man-
ner in previous reviews. In addition to pairwise meta-analysis 
that compared statins with control treatment, we performed 
network meta-analysis, which is a relatively new method that 
differs from pairwise meta-analysis by incorporating data 
from both direct (from trials that include a specific pairwise 
comparison) and indirect (from a network of trials that do not 
include that comparison) sources of evidence. We previously 
used this method to compare individual statins in terms of 
their cholesterol-lowering effects, as well as their effects on 
deaths, coronary events, and cerebrovascular events.44–46
Our findings show that there are statistically detectable dif-
ferences between individual statins in terms of their tolerabil-
ity, hepatic transaminase elevations, and CK elevations. At the 
drug level, individuals receiving simvastatin and pravastatin 
seem to have the lowest odds of experiencing myalgia, trans-
aminase and CK elevations, and discontinuations because of 
adverse events.
Our dose-specific analysis parallels the findings of previous 
meta-analyses in that more intensive statin therapy is associ-
ated with greater risk of harm and less favorable tolerability 
compared with lower doses.19,47–49 Similar to previous stud-
ies, we observed a general dose–response relationship across 
placebo-controlled and active-comparator trials in terms of 
discontinuations because of adverse events, transaminase ele-
vations, and CK elevations.
As with any meta-analysis, our network meta-analysis 
required an assumption of similarity across the pooled set of 
trials in terms of patient population and trial characteristics. 
More specifically, we assumed that the distribution of rela-
tive treatment effect modifiers (eg, baseline cholesterol lev-
els) was balanced across different treatment comparisons in 
the evidence network. An imbalance in the distribution of 
these variables in a single randomized, controlled trial would 
result in within-trial heterogeneity; an imbalance across 
0.00
0.20
0.40
0.60
0.80
1.00
Atorva Fluva Lova Prava Rosuva Simva Pitava
Discontinuations Myalgia Transaminase elevations CK elevations
Figure 6. Overall ranking of individual 
statins in placebo-controlled and active-
comparator trials of participants by 
their overall probability to be the best 
treatment in terms of discontinuations 
because of adverse events, myalgia, 
hepatic transaminase elevation, and CK 
elevation. In addition to the overall score 
for each statin, the relative contribution 
of each of the 4 outcomes to the overall 
score is also shown. Each statin was 
scored with points up to a maximum of 
0.25 for each outcome (overall maximum 
score: 1.00). Higher scores indicate a 
better tolerability and safety profile. CK 
indicates creatine kinase.
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trials would result in between-study heterogeneity in pairwise 
meta-analyses; and an imbalance across different treatment 
comparisons would result in inconsistency in network meta-
analyses, potentially biasing the results. To account for such 
imbalances, we evaluated several study-level characteristics in 
the meta-regression analyses. Specifically, our analyses sug-
gested that baseline mean age, low-density lipoprotein choles-
terol concentration, and trial publication year did not have an 
impact on the observed findings.
Findings of this study should be interpreted in light of its 
limitations. First, as a literature-based meta-analysis, our anal-
ysis shares the limitations of the published evidence base. The 
quality of included trials was moderate, with older trials being 
more prone to bias than newer trials. Second, given the large 
volume of available studies in the literature, our meta-analysis 
did not use individual patient-level data, which would have 
advantages when exploring potential differences across relative 
treatment effect modifiers. Third, although there was no evi-
dence of small-study effects, there was an apparent asymme-
try in the evidence network where specific interventions seem 
to be avoided (eg, fluvastatin). For instance, the relative effect 
of fluvastatin on CK elevations was estimated on the basis 
of 8 events observed in 4 trials including 2646 participants. 
Similarly, there were only 4 trials of fluvastatin, which reported 
hepatic transaminase elevations. As expected, the evidence 
base for pitavastatin was also sparse. Although pitavastatin was 
recently approved by the Food and Drug Administration, it has 
been in use in other settings since 2003 (most notably in Japan 
and South Korea) without a corresponding evidence base in 
the English language literature. Fourth, there was considerable 
heterogeneity across various pairwise meta-analyses of statins 
versus control, particularly for hepatic transaminase elevations. 
It remains a possibility that our analysis did not fully account 
for heterogeneity as a result of unobserved or unmeasured 
factors. However, we used a random-effects model, and our 
analyses took into account potential unexplained heterogene-
ity across the studies. We also performed meta-regressions to 
further evaluate heterogeneity and inconsistency and did not 
detect a significant effect of study-level characteristics.
Despite these limitations, our study has important method-
ological strengths. First, this review is the largest meta-anal-
ysis on the harms of statin therapy to date, including almost 
a quarter million trial participants. Second, we incorporated 
data from a comprehensive list of trials, irrespective of pla-
cebo or active controls, including all clinically used statins. In 
total, we included 80 active-comparator trials with or without 
a placebo or usual care arm. Third, we evaluated the dose-
comparative harms of individual statins.
Our findings have important clinical implications. First, 
there is strong evidence that statins as a class are generally 
safe with uncommon side effects. According to the findings 
of this comprehensive analysis, there is consistently strong 
evidence on the comparatively favorable side effect profile of 
simvastatin and pravastatin, particularly at low-to-moderate 
doses, which should be favored in clinical practice. This meta-
analysis sheds new light on the discussion of the relationship 
between statins and diabetes mellitus incidence and confirms 
that statin use is not associated with cancer incidence. Finally, 
we acknowledge the complex nature of making prescribing 
decisions and urge prescribers to consider the findings of this 
analysis in light of the comparative benefit profiles of indi-
vidual statins in preventing all-cause mortality in addition to 
cardiovascular and cerebrovascular events.44–46
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